Opthea Poised to Resume Trading on Australian Securities Exchange After Decision to Advance Lung Disease Drug Candidate
MT Newswires Live
Jun 03
Opthea (ASX:OPT) expects to resume trading on the Australian Securities Exchange on or around Wednesday following a decision to advance its OPT-302 drug candidate for the treatment of lymphangioleiomyomatosis, according to a same-day filing with the Australian bourse.
Lymphangioleiomyomatosis is a chronic lung disease that mainly affects women, characterized by the destruction of lung tissue.
Opthea believes its scientific assets, manufacturing capabilities, and intellectual property portfolio "provide a strong foundation" for a strategy focused on the disease, where a significant unmet medical need exists.
The company has launched a staged development program over an expected 18-month period to evaluate OPT-302, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.